US › Healthcare

Barinthus Biotherapeutics plc (BRNS)

US · Healthcare · Biotechnology

$0.56-5.87%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.5M
Profit YoY
+71.9%
EPS
$-0.14
EPS estimate
$-0.28

EPS came in at -0.14 against a street estimate of -0.28 — a beat of 50.0%.

Key statistics

Market cap
$24.5M
Forward P/E
0.0
P/B
0.34
Book value
$1.62
EPS (TTM)
$-1.29
52-week high
$1.83
52-week low
$0.51
50-day MA
$0.65
200-day MA
$0.72
Beta
-0.39

Analyst view

Analysts rate Barinthus Biotherapeutics plc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $5.50.

Shareholding

Insiders
19.81%
Institutions
44.30%

Largest institutional holders

FundStake
M&G PLC12.72%
HSG Holding Ltd3.48%
GLR Partners, LLC3.04%
DC Funds, LP1.57%
Renaissance Technologies Corp0.37%
The Johns Hopkins University0.30%
Citadel Advisors Llc0.29%
Baird Financial Group, Inc.0.26%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Barinthus Biotherapeutics plc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.